LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo. The objective was to form that using LGD-4033 was harmless and easy to stomach with a dose not beyond 22 mg a day.
Clinical runs also showed that LGD-4033 has the ability to set off the following benefits when taken consistently:
An increase in strength levels
Lean muscle mass improved
A drop in body fat
Has healing properties
Does not cause the undesirable side effects caused by prohormones and anabolic steroids
When to Use LGD-4033
Based on some latest studies and experiments conducted, LGD-4033 can enhance lean muscle mass and decrease body fat. Also, it can boost strength for better and more challenging training performance, recovery and overall health. Thus, it comes as no surprise that athletes and bodybuilders use LGD-4033 to help them be in their best selves.
For Bulking | Suggested dosage is 5-10 mg a day for 8 weeks. A protein-rich diet is also necessary as well as higher caloric intake if you plan to beef up by 10 pounds or more. |
For Cutting | Use LGD-4033 with SARMS triple pack (GW-501516, S-4 and LGD-4033) to make it more effective as you are aiming to add more size while cutting fat. Suggested dosage is 3-5 mg a day for 8 weeks. |
For Recomping | LGD-4033 is best used for recomping. Many users have said that they've observed a boost in lean body mass and fat loss. Using it together with other SARMS such as or Cardarine will give you a stronger and better recomp. Suggested dosage is 5-8 mg per day for 8 weeks. |
Product name: LGD-4033
Synonyms: Ligandrol
CAS: 1165910-22-4
MF: C14H12F6N2O
MW: 338.2482992
Apperance: White Crystalline Powder
Name | NO. | Usage |
RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
MK-677 | 15972-10-0 |
A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
MK2866 | 841205-47-8 |
medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
SR9009 | 1379686-30-2 |
under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
Aicar | 2627-69-2 |
acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |